Do newer IQOS devices change how people puff? study investigates

NCT ID NCT07712887

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study compares how people use two generations of IQOS heated tobacco devices—the newer IQOS Iluma i and the older IQOS 2.4—and how each affects their smoking behavior and sensory experience. Participants attend two lab visits, use both devices, and have their puffing patterns recorded. The goal is to see if device design or tobacco stick flavor influences puffing, throat hit, and satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IQOS Iluma i and IQOS 2.4 heated tobacco devices
What this could lead to
If it works, this could help understand how newer heated tobacco devices affect user behavior and satisfaction.
What could go wrong
This is a small, early-stage study with only 50 participants, so results may not apply to all users. It does not test health effects or long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current IQOS user (at least 3 days per week in the past 30 days) * Age 18 to 65 years * Generally healthy * Willing to provide informed written consent * Willing to attend all laboratory visits * Willing to abstain from all nicotine and tobacco products for at least 12 hours before each visit Exclusion Criteria: * Use of any tobacco products other than IQOS in the past 30 days * Chronic cardiovascular conditions, seizures, or abnormal blood pressure * Current psychiatric disorder requiring active treatment, including major depressive disorder * Regular use of prescription medications that may influence cardiovascular function, respiratory function, or nicotine metabolism (excluding vitamins or birth control) * Use of cocaine, opioids, benzodiazepines, or methamphetamines in the past month * Marijuana use on more than 15 days per month * Current pregnancy or breastfeeding * Plans to quit nicotine or tobacco products within the next 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nicotine dependence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nicotine dependence Tobacco Use Vaping

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut

    RECRUITING

    Beirut, Beirut, 1107 2020, Lebanon

  • Clinical Aerosol Technology Laboratory (CATLAB), American University of Beirut

    RECRUITING

    Beirut, Lebanon

More trials for these conditions

Other studies related to the condition(s) this trial covers.